3D Tissue Models

View Profile


Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors Review type Summary Keywords File filename File mime type
1. 2009 Intracellular clusterin inhibits mitochondrial apoptosis by suppressing p53-activating stress signals and stabilizing the cytosolic Ku70-Bax protein complex Clinical Cancer Research, 15(1): 48-51.
2. 2009 Interleukin-6 affects cell death escaping mechanisms acting on bax-Ku70-clusterin interactions in human colon cancer progression Cell Cycle 8(3): 1-9
3. 2009 Intratumoral Implantation of ß-Lapachone-encapsulated Polymer Millirod For Prostate Cancer Therapy. Clinical Cancer Res., 15(1): 131-139.
4. 2009 Loss of p15/Ink4b accompanies tumorigenesis triggered by particle radiation EMBO J., In Prep
5. 2009 Low-dose ionizing radiation-inducible clusterin promoter Imaging and application in biodosimetry. Manuscript in preparation, 2009.
6. 2009 Turning the superparamagnetic nanoprobes for cancer molecular imaging. Cancer Research, 69(4): 1651-8.
7. 2009 TGF-ß1 regulation of the murine double minute protein and its control of epithelial-to-mesenchymal transition. J. Clinical Investigation, In Revision,
8. 2009 Regulation of the clusterin promoter by TGF-ß1 involves Smad activation Molecular Cell, In Revision
9. 2009 ß-Lapachone micelle nanotherapeutics for non-small cell lung cancer. J. Natl Cancer Institute, Submitted.
10. 2009 CRM1-mediated nuclear export of nuclear clusterin (nCLU), a pro-death protein activated by ionizing radiation. J. Biological Chemistry, Submitted, 2009.
11. 2009 The role of DAB2IP in modulating epithelial-to-mesenchymal transition (EMT) and prostate cancer metastasis. PNAS, Submitted (Dr. G. Stark, ed.).
12. 2009 Global germline and tumor microsatellite patterns are cancer biomarkers Nature Medicine, Submitted.
13. 2009 TGF-ß-induced expression of Hdm2 correlates with late stage metastatic breast cancer J. Clinical Investigation, In Press
14. 2009 Dual PI3K/mTOR blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Research, In Press.
15. 2009 Vanadium-induced apoptosis of HaCaT cells is mediated by c-fos and involves nuclear accumulation of clusterin. FEBS J, 276(14): 3784-3799.
16. 2009 RIP1 activates PI3K-Akt via a dual mechanism involving NF-kappaB mediated inhibition of the mTOR-S6K-IRS1 negative feedback loop and downregulation of PTEN Cancer Res., 69(10): 4107-4115.
17. 2009 EGFRvIII and DNA Double-Strand Break Repair: A Molecular Mechanism for Radioresistance in Glioblastoma. Cancer Research, 69(10): 4252-4259.
18. 2009 The receptor interacting protein (RIP1) inhbits p53 induction through NF-kB activation and confers a worse prognosis in glioblastoma. Cancer Research, 69(7): 2809-2816.
19. 2008 DNA mismatch repair-dependent activation of c-Abl/p73a/GADD45a-mediated apoptosis. J. Biological Chemistry 283: 21394-21403.
20. 2008 Role of c-Abl in MMR-dependent G2 arrest responses. J. Biological Chemistry 283: 21382-21393.
21. 2007 Use of ß-lapachone for therapy against nonsmall cell lung cancer. Proc. Natl. Acad., Sci., USA 104: 11832-7.
22. 2007 NQO1-dependent ROS create threshold levels of DNA damage required for PARP-1 hyperactivation in b-lapachone-induced cell death. Free Rad. Biol., submitted.
23. 2007 Bax-inhibiting peptides derived from Ku70 and cell-penetrating pentapeptides Biochem. Soc., Trans. 35: 797-801.
24. 2007 Radiation-induced up-regulation of NAD(P)H:quinone oxidoreductase (NQO1) potentiates the effect of bioreductive ß-lapachone against cancer cells Mol Cancer Ther., 9: 634-642.
25. 2007 Modulating ß-lapachone release from polymer millirods through cyclodextrin complexation J. Control Release, 122: 365-374.
26. 2007 Nonhomologous end joining recombination is a resistance factor to NQO1- ß-lapachone Cancer Res., 67: 6936-45.
27. 2007 Clusterin over-expression modulates proapoptotic and antiproliferative effects of 1,25(OH)(2)D(3) in prostate cancer cells in vitro J. Steroid Biochemistry and Molecular Biology 103(35): 721-725.
28. 2006 Clusterin (CLU) and melanoma growth: CLU is expressed in malignant melanoma and 1,25-dihydroxyvitamin D3 modulates expression of CLU in melanoma cell lines in vitro. Anticancer Res. 26: 2707-2716.
29. 2006 Calcium regulation of PARP-1 hyperactivation for altered cellular metabolism and inhibition of DNA repair J Biological Chemistry, 261(44): 33684-33696.
30. 2006 Modulating ß-lapachone release from polymer millirods through cyclodextrin complexation. J. Pharmaceutical Sciences, 2006; 95(10): 2309-2319.
31. 2006 Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer Cell Death and Differentiation. 2006; 13(1): 12-19.
32. 2006 Multifunctional polymeric micells as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nanoletters 6 (11): 2427-2430.
33. 2005 Delayed activation of IGF-1R/Src/MAPK signaling after IR regulates clusterin expression, a pro-survival protein J. Biological Chemistry 280(14): 14212-14221.
34. 2005 Efficacy of ß-lapachone in pancreatic cancer treatment: Exploiting the novel, therapeutic target NQO1. Cancer Biology and Therapy, 4 (1): 54-61.
35. 2005 Interactions between Self-Assembled Polyelectrolyte Shells and Tumor Cells Journal of Biomedical Materials Research, 73(3): 303-312.
36. 2005 Not Mentioned Clinical Cancer Research, 11(24): 8866-8871.
37. 2005 Radiation increases the sensitivity of cancer cells to ß-lapachone. Int. J. Rad. Oncol., Biol., & Phys, 61(1): 212-219.
38. 2005 Development of β-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels Clinical Cancer Research, 11(8): 3055-3064.
39. 2005 Clusterin proteins: stress-inducible polypeptides with proposed functions in multiple organ dysfunction. British Journal of Radiology 27: 106-113.
40. 2004 Role of DNA mismatch repair in apoptotic responses to therapeutic agents. Environ. Mol. Mutagen, 44(4): 249-264.
41. 2004 DNA mismatch repair detection and cellular responses to damage caused by 5-fluoro-2’-deoxyuridine exposure J. Biological Chemistry, 280(7): 5516-5526.
42. 2004 cRGD-functionalized polymer micelles for targeted doxorubicin or ß-lapachone delivery Angew Chem. Int. Ed. Engl., 43(46): 6323-6327.
43. 2004 A phase I study of Topotecan, as a radiosensitizer for thoracic malignancies Lung Cancer 44(1): 111-119.
44. 2004 IR-inducible clusterin gene expression: a protein with potential roles in ionizing radiation-induced adaptive responses, genomic instability, and bystander effects Mutation Research, 568(1): 97-110.
45. 2004 Clusterin: a protein with multiple functions as a potential ionizing radiation exposure marker International Congress Series 27: 2784-93.
46. 2003 Synthesis and functional analyses of nuclear clusterin, a cell death protein J. Biological Chemistry 278(13): 11590-11600.
47. 2003 µ-Calpain activation in ß-lapachone-mediated apoptosis. Cancer Biology & Therapy 2(2): 141-152.
48. 2003 Enhancement of solubility and bioavailability of ß-lapachone using cyclodextrin inclusion complexes. J. Pharmacological Research 20(10): 1626-1633.
49. 2003 A role for DNA mismatch repair in sensing and responding to fluoropyrimidine damage Oncogene 22: 7376-7388
50. 2003 Transcriptional Repression of Clusterin by the p53 Tumor Suppressor Protein. Cancer Biology and Therapy 2(4): 25-31.
51. 2003 Ku70 suppresses the apoptotic translocation of Bax to mitochondria. Nature Cell Biology 5(4): 320-329.
52. 2002 Calpains and apoptosis. Korean J. Biological Science 5: 267-274.
53. 2001 ß-Lapachone-induced apoptosis in human prostate cancer cells: involvement of NQO1/xip3. Experimental Cell Research 267: 95-106.
54. 2001 Calcium is a key signaling molecule in ß-lapachone-mediated cell death. J. Biological Chemistry 276(22): 19150-19159.
55. 2001 Role of DNA mismatch repair in FdUrd-mediated cytotoxicity. Cancer Research 61(13): 5193-5201.
56. 2001 Mismatch repair mediated a proficient G2 arrest and cdc2 phosphorylation following high-dose rate ionizing radiation Cancer Research 61(22): 8290-8297.
57. 2000 Coordinate modulation of Sp1, NF-kappa B, and p53 in confluent human malignant melanoma cells after ionizing radiation. FASEB Journal 14(2): 379-390.
58. 2000 Cellular and Molecular Responses to Topoisomerase I Poisons: Exploiting Synergy For Improved Radiotherapy. Annals of the New York Academy of Sciences 922: 274-292.
59. 2000 Upregulation of clusterin during photodynamic therapy-mediated apoptosis of tumor cells and ablation of mouse skin tumors. Cancer Research 60(21): 5984-5987.
60. 2000 Nuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals cell death Proc. Natl. Acad. Sci., USA 97(11): 5907-5912.
61. 2000 NF-kB activation by camptothecin: A linkage between nuclear DNA damage and cytoplasmic signaling events J. Biological Chemistry 275(13): 9501-9509.
62. 2000 A novel non-caspase-mediated proteolytic pathway activated in breast cancer cells during ß-lapachone-mediated apoptosis. Experimental Cell Research 255 (2): 144-155.
63. 2000 NAD(P)H:quinone oxidoreductase (NQO1) activity is the principal determinant of ß-lapachone cytotoxicity. J. Biological Chemistry 275(8): 5416-5422.
64. 1999 bcl-2 protects against caspase 3-mediated apoptosis induced by ß-lapachone Oncology Reports 6: 485-492.
65. 1999 Delayed apoptotic responses associated with radiation-induced neoplastic transformation of human hybrid cells. Cancer Research 59(16): 3972-3979.
66. 1999 Nieman-Pick human lymphoblasts are resistant to phthalocyanine 4-photodynamic therapy-induced apoptosis. Biomedical Biophysics Research Communication 258: 506-512.
67. 1999 Combined radiation and p53 gene therapy of malignant glioma cells. Cancer Gene Therapy 6: 155-162.
68. 1999 Isolation of Ku70 binding proteins (KUBs) Nucleic Acids Research 27: 2165-2174.
69. 1999 The mismatch repair protein, hMHL1, mediates 5-substituted halogenated thymidine analog cytotoxicity, DNA incorporation and radiosensitization in human colon cancer cells. Cancer Research 59: 1840-1845.
70. 1998 Adenovirus-mediated p53 gene delivery potentiates the radiation-induced growth inhibition of experimental brain tumors. J. Neuro-Oncology 37: 217-222.
71. 1998 Molecular analyses of adaptive survival responses (ASRs): role of ASRs in radiotherapy. Human and Experimental Toxicology 17: 448-453.
72. 1998 Apoptosis, reproductive failure, and oxidative stress in Chinese hamster ovary cells with compromised genomic integrity. Cancer Research 58: 3712-3718.
73. 1998 ß-Lapachone-induced apoptosis in MCF-7 human breast cancer cells Cancer Research 58: 1876-1885.
74. 1998 DNA-dependent protein kinase (DNA-PK) does not play a role in adaptive survival responses to ionizing radiation. Perspectives in Environmental Health Sciences 106: 301-305.
75. 1998 Defective expression of the DNA mismatch repair protein, hMLH1, alters G2/M arrest following ionizing radiation. Cancer Research 58(4): 767-778.
76. 1997 Reversed-phase high-performance liquid chromatography method for determination of beta-lapachone and 3-hydroxy-beta-lapachone in plasma J. Chromatography 692 (2): 181-186.
77. 1997 Chromosome instability and its relationship to other endpoints of genomic instability. Cancer Research 57(24): 5557-5563.
78. 1997 Damage sensing mechanisms in human cells after ionizing radiation. Stem Cells 15: 27-42.
79. 1997 Cell cycle regulation of the human DNA mismatch repair genes, hMSH-2, hMLH-1 and hPMS-2. Cancer Research 57(2): 206-208.
80. 1996 Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation Int. J. Radiat. Oncol. Biol. Phys. 36(2): 361-368.
81. 1996 Altered G1 checkpoint control determines adaptive survival responses to ionizing radiation. Mutation Research 358(2): 143-153.
82. 1996 Radiation lethality enhancement with 9-aminocamptothecin: comparison to other topoisomerase I inhibitors Int. J. Radiat. Oncol. Biol. Phys. 36(2): 369-376.
83. 1996 The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: review of the synergistic effect between topotecan and radiation. J. Neuro-Oncology 30(1): 1-6.
84. 1995 ß-Lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response Cancer Research 55: 3706-3711.
85. 1994 Enhanced expression of thymidine kinase in human cells following ionizing radiation. Int. J. Rad. Oncol. Biol. Phys. 30(2): 391-398.
86. 1994 Down-regulation of topoisomerase I following ionizing radiation in mammalian cells Cancer Research 54: 4618-4626.
87. 1994 Isolation of an X-Ray-Responsive Element (XRE) in the promoter region of tissue-type plasminogen activator: potential uses of XREs for gene therapy? Radiation Research 138: 68-71
88. 1994 Alterations in transcription factor binding in radioresistant human melanoma cells following ionizing radiation. Radiation Research 138: 47-51.
89. 1994 Enhanced malignant transformation is accompanied by increased survival recovery following ionizing radiation in Chinese hamster embryo fibroblast cells. Radiation Research 138: 121-125
90. 1994 Immediate X-ray-inducible responses from mammalian cells Radiation Research 138: 44-46.
91. 1993 Isolation of X-ray-inducible transcripts from radioresistant human melanoma cells Proc. Natl. Acad. Sci., USA 90 (15): 7200-7204.
92. 1992 Posttreatment exposure to camptothecin enhances the lethal effects of X-rays on radioresistant human malignant melanoma cells. Int. J. Radiat. Oncol. Biol. Phys 24: 939-948.
93. 1992 Enhanced induction of tissue-type plasminogen activator in normal human cells compared to cancer-prone cells following ionizing radiation. Int. J. Radiat. Oncol. Biol. Phys. 24: 949-957.
94. 1992 Regulation of gene expression in mammalian cells following ionizing radiation. Yokohama Medical Bulletin 42:137-149.
95. 1991 Effect of caffeine on the expression of a major X-ray-induced protein in human tumor cells Radiation Research 125: 313-317.
96. 1991 Induction of tissue-type plasminogen activator by ionizing radiation in human malignant melanoma cells. Cancer Research 51: 5587-5595
97. 1990 Radiation, pool size and incorporation studies in mice with 5-chloro-2'-deoxycytidine. Int. J. Radiat. Oncol. Biol. Phys. 19: 357-365.
98. 1989 Inhibition of potentially lethal DNA damage repair in human tumor cells by ß-lapachone, an activator of topoisomerase I. Cancer Research 49: 605-612.
99. 1989 Identification and characterization of X-ray-induced proteins in human cells Cancer Research 49: 2871-2878.
100. 1989 Expression of the E. coli Lac Z gene from a defective HSV-1 vector in various human normal, cancer-prone and tumor cells. FEBS Letters 258: 159-162.
101. 1989 Inhibition of radiation-induced neoplastic transformation by ß-lapachone Proc. Natl. Acad. Sci., USA 86: 4963-4967.
102. 1988 Anticarcinogenic potential of DNA-repair inhibitors. Mutation Research 202: 393-411.
103. 1987 Protective, tumor-selective dual pathway activation of 5-fluoro-2'-deoxycytidine provided by tetrahydrouridine in mice bearing mammary adenocarcinoma-755 Cancer Research 47: 2344-2353.
104. 1987 Potentiation of halogenated pyrimidine radiosensitizers by ß-lapachone (3,4-dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione), a novel DNA repair inhibitor Cancer Research 47: 5361-5366.
105. 1987 Tumor-selective metabolism of 5-fluoro-2'-deoxycytidine coadministered with tetrahydrouridine compared to 5-fluorouracil in mice bearing Lewis lung carcinoma Cancer Research 47: 2354-2362.
106. 1986 Analysis of 5-fluoro-2'-deoxycytidine and 5-trifluoromethyl-2'-deoxycytidine and their related antimetabolites by high performance liquid chromatography J. Chromatography 381: 343-356.
107. 1985 Metabolic channeling of 5-fluoro-2'-deoxycytidine utilizing inhibitors of its deamination in cell culture Molecular Pharmacology 27: 584-594.
108. 1985 Use of trifluoromethyl-deoxycytidine and tetrahydrouridine to circumvent catabolism and exploit high levels of cytidine deaminase in tumors to achieve DNA- and target-directed therapies. Cancer Research 45: 5270-5280.
109. 1984 Use of 5- fluorodeoxycytidine and tetrahydrouridine to exploit high levels of deoxycytidylate deaminase in tumors to achieve DNA- and target-directed therapy Cancer Research 44: 2551-2560


About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.